February 15, 2018
Celgene’s Otezla better than placebo in a phase 2 test
Celgene Corporation said that a higher proportion of patients taking apremilast 30 mg twice daily (BID) achieved clinical remission versus placebo.…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
February 15, 2018
BASF joins the World Plastics Council
BASF ahs joined the World Plastics Council (WPC), a global organization of key leaders in the plastics industry. The WPC…
February 14, 2018
Celgene in additional $5 Billion share repurchase
Celgene Corporation has authorized the repurchase of an additional $5 billion of its common stock. As the company noted, the…
February 14, 2018
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
Novartis and the Bill & Melinda Gates Foundation have formed an alliance to advance development of Novartis’ drug candidate KDU731…
February 13, 2018
Lilly’s Taltz meets enpoints in phase 3 study of Taltz for treating painful spine due to radiographic axial spondyloarthritis
Eli Lilly said on Tuesday that its Ankylosing Spondylitis treatment candidate, Taltz met the primary and all key secondary endpoints…
February 13, 2018
Vertex offers Symdeko for more cystic fibrosis patients
Vertex Pharmaceuticals Incorporated can now offer Symdeko for treating the underlying cause of cystic fibrosis (CF) for more certain patients.…
February 13, 2018
BD with pre-market approval from FDA for BD Onclarity HPV assay
BD has received pre-market approval from the U.S. Food and Drug Administration for the BD Onclarity HPV assay, the company…
February 12, 2018
Actinium seeks chance to maximize value for partners and collaborators, applies Acute Myeloid Leukemia treatment for investigation
Actinium Pharmaceuticals has applied an Investigational New Drug for Actimab-A combined with CLAG-M, for Acute Myeloid Leukemia, to the USFDA.
February 12, 2018
Audent Therapeutics starts dosing patients for rare pediatric disease Crigler-Najjar Syndrome, as it tests recently fast tracked AT342
Audentes Therapeutics has started with dosing of patients in a Phase 1/2 clinical trial of its product candidate AT342 for…
February 12, 2018
Santen’s has potential treatment for patients with wet AMD
Santen’s topline results from the Phase I/II study of DE-122 for refractory wet age-related macular degeneration (AMD) suggest bioactivity of DE-122…